tetano
Editor, Senior Moderator
Sci Rep
. 2023 Dec 1;13(1):21249.
doi: 10.1038/s41598-023-48145-x. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
Mary J Kasten[SUP] 1 [/SUP], Brian D Lahr[SUP] 2 [/SUP], Anusha Parisapogu[SUP] 3 [/SUP], Zachary A Yetmar[SUP] 4 5 [/SUP], John C O'Horo[SUP] 4 6 [/SUP], Robert Orenstein[SUP] 7 [/SUP], Pablo Moreno Franco[SUP] 8 [/SUP], Raymund R Razonable[SUP] 4 [/SUP], Paschalis Vergidis[SUP] 4 [/SUP], Aditya S Shah[SUP] 4 [/SUP], Mark J Enzler[SUP] 4 [/SUP], David J Inwards[SUP] 9 [/SUP], Philippe R Bauer[SUP] 10 11 [/SUP]
Affiliations
The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy within the 3 years prior to infection. We compared outcomes between those treated with and those not treated with high titer SARS-CoV2 convalescent plasma. We identified 144 adults treated at Mayo clinic sites who had received anti-CD20 therapies within a median of 5.9 months prior to the COVID-19 index date. About one-third (34.7%) were hospitalized within 14 days and nearly half (47.9%) within 90 days. COVID-19 directed therapy included anti-spike monoclonal antibodies (n = 30, 20.8%), and, among those hospitalized within 14 days (n = 50), remdesivir (n = 45, 90.0%), glucocorticoids (n = 36, 72.0%) and convalescent plasma (n = 24, 48.0%). The duration from receipt of last dose of anti-CD20 therapy did not correlate with outcomes. The overall 90-day mortality rate was 14.7%. Administration of convalescent plasma within 14 days of the COVID-19 diagnosis was not significantly associated with any study outcome. Further study of COVID-19 in CD20-depleted individuals is needed focusing on the early administration of new and potentially combination antiviral agents, associated or not with vaccine-boosted convalescent plasma.
. 2023 Dec 1;13(1):21249.
doi: 10.1038/s41598-023-48145-x. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
Mary J Kasten[SUP] 1 [/SUP], Brian D Lahr[SUP] 2 [/SUP], Anusha Parisapogu[SUP] 3 [/SUP], Zachary A Yetmar[SUP] 4 5 [/SUP], John C O'Horo[SUP] 4 6 [/SUP], Robert Orenstein[SUP] 7 [/SUP], Pablo Moreno Franco[SUP] 8 [/SUP], Raymund R Razonable[SUP] 4 [/SUP], Paschalis Vergidis[SUP] 4 [/SUP], Aditya S Shah[SUP] 4 [/SUP], Mark J Enzler[SUP] 4 [/SUP], David J Inwards[SUP] 9 [/SUP], Philippe R Bauer[SUP] 10 11 [/SUP]
Affiliations
- PMID: 38040756
- DOI: 10.1038/s41598-023-48145-x
The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy within the 3 years prior to infection. We compared outcomes between those treated with and those not treated with high titer SARS-CoV2 convalescent plasma. We identified 144 adults treated at Mayo clinic sites who had received anti-CD20 therapies within a median of 5.9 months prior to the COVID-19 index date. About one-third (34.7%) were hospitalized within 14 days and nearly half (47.9%) within 90 days. COVID-19 directed therapy included anti-spike monoclonal antibodies (n = 30, 20.8%), and, among those hospitalized within 14 days (n = 50), remdesivir (n = 45, 90.0%), glucocorticoids (n = 36, 72.0%) and convalescent plasma (n = 24, 48.0%). The duration from receipt of last dose of anti-CD20 therapy did not correlate with outcomes. The overall 90-day mortality rate was 14.7%. Administration of convalescent plasma within 14 days of the COVID-19 diagnosis was not significantly associated with any study outcome. Further study of COVID-19 in CD20-depleted individuals is needed focusing on the early administration of new and potentially combination antiviral agents, associated or not with vaccine-boosted convalescent plasma.